Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jul 10:8:14.
doi: 10.1186/s13569-018-0101-2. eCollection 2018.

Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature

Nicholas Giustini  1 , Nicholas M Bernthal  2 , Susan V Bukata  2 , Arun S Singh  1
Affiliations
Case Reports

Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature

Nicholas Giustini et al. Clin Sarcoma Res. .

Abstract

Background: Tenosynovial giant cell tumors (TGCTs) or giant cell tumors of tendon sheath are neoplasms that arise in the synovium. They can be categorized as nodular (localized) or diffuse type (D-TGCT). Historically, surgery has been the mainstay of therapy, but diffuse type disease recurs at a high rate and treatment often requires increasingly morbid procedures. Elucidation of the importance of the colony-stimulating factor (CSF1)/CSF1 receptor (CSF1R) pathway in the pathogenesis of this disease has created significant interest in targeting this pathway as a novel TGCT treatment approach. Pexidartinib, a selective tyrosine kinase inhibitor against CSF1R, showed an 83% disease control rate (52% with partial response and 31% with stable disease) in a recent phase 1 study of patients with TGCT.

Case presentation: We present an illustrative example of a TGCT patient who would have required a morbid operation who derived considerable clinical benefit from pexidartinib treatment. Her tumor volume decreased by 48% after 4 months of treatment, and 55 months after starting treatment the patient exhibits continued disease stability with minimal clinical symptoms, and significant improvement in functional status.

Conclusions: This case illustrates the effectiveness of systemic therapy in controlling a disease associated with high surgical morbidity. This approach may be especially useful in the treatment of extra-articular disease which often invades neurovascular bundles; as the effectiveness in metastatic disease is still unknown. In the future, systemic treatment for TGCT may be appropriate for the neoadjuvant setting to decrease disease burden prior to surgery with the aim of decreasing recurrence rates. However, properly designed prospective studies will need to be carried out to answer these questions.

Keywords: CSF1; Case report; GCT-TS; Giant cell tumor of tendon sheath; PLX3397; PVNS; Pexidartinib; Pigmented villonodular synovitis; TGCT; Tenosynovial giant cell tumor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
MRI scan of suprapatellar aspect in January 2013 (a) and May 2017 (b)
See this image and copyright information in PMC

References

    1. de Saint Aubain Somerhausen NS, van de Rijn M. Tenosynovial giant cell tumor: localized type, diffuse type. In: Fletcher C, Bridge J, Hogendoorn P, Martens F, editors. World Health Organization classification of tumours of soft tissue and bone. Lyon: IARC Press; 2013. pp. 100–103.
    1. Monaghan H, Salter DM, Al-Nafussi A. Giant cell tumour of tendon sheath (localised nodular tenosynovitis): clinicopathological features of 71 cases. J Clin Pathol. 2001;54:404–407. doi: 10.1136/jcp.54.5.404. - DOI - PMC - PubMed
    1. Ottaviani S, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum. 2011;40:539–546. doi: 10.1016/j.semarthrit.2010.07.005. - DOI - PubMed
    1. Mastboom MJL, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017;88:688–694. doi: 10.1080/17453674.2017.1361126. - DOI - PMC - PubMed
    1. Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol. 2011;23:361–366. doi: 10.1097/CCO.0b013e328347e1e3. - DOI - PubMed

Publication types